Nivolumab Added to Cisplatin and Radiotherapy Improves DFS in Patients with High-Risk Resected Locally Advanced SCCHN By Ogkologos - January 9, 2026 174 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the GORTEC 2018-01 NIVOPOST-OP study Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR Sasanlimab Prolongs EFS When Combined with BCG Induction and Maintenance in... July 22, 2025 Starving cancer into submission January 30, 2023 Immunotherapy’s Role in Treating Endometrial Cancer Expected to Grow April 12, 2023 Nous-209 Efficiently Stimulates Immunity Against Neoantigens in Lynch Syndrome Carriers February 3, 2026 Load more HOT NEWS ESMO Sarcoma and Rare Cancers Congress 2024 For Cancer Screening, COVID-19 Pandemic Creates Obstacles, Opportunities Aggressive Prostate Cancer Subtype More Common Than Expected Doctors Think Woman Has A Brain Tumor, But Then They Open...
